(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz - 2The Electric Bicycle Americans Can Confide in 2024
- 3SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- 4Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 5Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- The Best 15 Applications for Efficiency and Association
- The 10 Most Significant Virtual Entertainment Missions
- Foreign journalist kidnapped in Iraq: Interior Ministry
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- Fundamental Home Items Each Animal person Needs
- Ergonomic Office Seats for Work spaces
